NASDAQ:MGNX - US5560991094 - Common Stock
Taking everything into account, MGNX scores 3 out of 10 in our fundamental rating. MGNX was compared to 547 industry peers in the Biotechnology industry. While MGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, MGNX is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.83% | ||
ROE | -78.08% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 86.91% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -6.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.26 | ||
Quick Ratio | 5.02 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.64
-0.05 (-2.96%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.63 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.22 | ||
P/tB | 2.22 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -14.83% | ||
ROE | -78.08% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 86.91% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 32.46% | ||
Cap/Sales | 1.48% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.26 | ||
Quick Ratio | 5.02 | ||
Altman-Z | -6.36 |